Protagonist Therapeutics, Inc. (PTGX)
NASDAQ: PTGX · Real-Time Price · USD
56.72
+2.19 (4.02%)
Aug 13, 2025, 4:00 PM - Market closed
Protagonist Therapeutics Employees
Protagonist Therapeutics had 126 employees as of December 31, 2024. The number of employees increased by 14 or 12.50% compared to the previous year.
Employees
126
Change (1Y)
14
Growth (1Y)
12.50%
Revenue / Employee
$1,660,159
Profits / Employee
$413,000
Market Cap
3.53B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
PTGX News
- 7 days ago - Protagonist Reports Second Quarter 2025 Financial Results and Provides Corporate Update - Accesswire
- 7 weeks ago - Protagonist Therapeutics to Host Conference Call to Announce an Oral Obesity Development Candidate - Accesswire
- 7 weeks ago - Protagonist Therapeutics: Two 'Slam Dunk' Sets Of Pivotal Data Set Up Bull Case - Seeking Alpha
- 2 months ago - Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera - Business Wire
- 3 months ago - Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2025 - Accesswire
- 3 months ago - Protagonist Reports First Quarter 2025 Financial Results and Provides Corporate Update - Accesswire
- 4 months ago - Protagonist Therapeutics Announces Plenary Presentation on VERIFY Phase 3 Study with Rusfertide at ASCO 2025 - Accesswire
- 4 months ago - Protagonist Therapeutics Reports Granting of Inducement Award - Accesswire